(FMED) Fidelity Disruptive Medicine - Ratings and Ratios
Exchange: NASDAQ • Country: USA • Currency: USD • Type: Etf • ISIN: US3160921470 • Health
FMED: Genomics, Gene, Editing, Cancer, Therapies, Diagnostics
The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.
Additional Sources for FMED ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
FMED ETF Overview
| Market Cap in USD | 53m |
| Category | Health |
| TER | 0.50% |
| IPO / Inception | 2020-04-16 |
FMED ETF Ratings
| Growth 5y | 22.1% |
| Fundamental | - |
| Dividend | 21.7% |
| Rel. Strength Industry | -68.9 |
| Analysts | - |
| Fair Price Momentum | 23.97 USD |
| Fair Price DCF | - |
FMED Dividends
| Dividend Yield 12m | 0.43% |
| Yield on Cost 5y | 0.45% |
| Annual Growth 5y | -100.00% |
| Payout Consistency | 100.0% |
FMED Growth Ratios
| Growth Correlation 3m | -38.1% |
| Growth Correlation 12m | 58.1% |
| Growth Correlation 5y | 59.7% |
| CAGR 5y | 2.22% |
| CAGR/Mean DD 5y | 0.39 |
| Sharpe Ratio 12m | 0.30 |
| Alpha | -15.22 |
| Beta | 0.85 |
| Volatility | 16.89% |
| Current Volume | 5.4k |
| Average Volume 20d | 6.7k |
What is the price of FMED stocks?
As of January 23, 2025, the stock is trading at USD 26.07 with a total of 5,448 shares traded.
Over the past week, the price has changed by +2.99%, over one month by +4.00%, over three months by +0.06% and over the past year by +8.33%.
As of January 23, 2025, the stock is trading at USD 26.07 with a total of 5,448 shares traded.
Over the past week, the price has changed by +2.99%, over one month by +4.00%, over three months by +0.06% and over the past year by +8.33%.
Is Fidelity Disruptive Medicine a good stock to buy?
Neither. Based on ValueRay Analyses, Fidelity Disruptive Medicine is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 22.06 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of FMED as of January 2025 is 23.97. This means that FMED is currently overvalued and has a potential downside of -8.06%.
Neither. Based on ValueRay Analyses, Fidelity Disruptive Medicine is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 22.06 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of FMED as of January 2025 is 23.97. This means that FMED is currently overvalued and has a potential downside of -8.06%.
Is FMED a buy, sell or hold?
Fidelity Disruptive Medicine has no consensus analysts rating.
Fidelity Disruptive Medicine has no consensus analysts rating.
What are the forecast for FMED stock price target?
According to ValueRays Forecast Model, FMED Fidelity Disruptive Medicine will be worth about 26.5 in January 2026. The stock is currently trading at 26.07. This means that the stock has a potential upside of +1.73%.
According to ValueRays Forecast Model, FMED Fidelity Disruptive Medicine will be worth about 26.5 in January 2026. The stock is currently trading at 26.07. This means that the stock has a potential upside of +1.73%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 26.5 | 1.7% |